Jessica Serra | Head of Investor Relations and ESG |
Mark Foley | President and Chief Executive Officer |
Toby Schilke | Chief Financial Officer |
Roman Rubio | Senior Vice President Clinical Development |
Dustin Sjuts | Chief Commercial Officer, Therapeutics & Aesthetics |
Abhay Joshi | Chief Operating Officer and President of R&D and Product Operation |
Ken Cacciatore | Cowen and Company |
Seamus Fernandez | Guggenheim |
Terence Flynn | Goldman Sachs |
Annabel Samimy | Stifel |
Balaji Prasad | Barclays |
David Amsellem | Piper Sandler |
Jacob Hughes | Wells Fargo |
Tim Lugo | William Blair |
Serge Belanger | Needham & Company |
Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2020 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode.
Following managements' prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this call is being recorded today, February 22, 2021. I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations and ESG for Revance.